The Sigma Enigma: A Narrative Review of Sigma Receptors
暂无分享,去创建一个
C. Moussa | G. Varrassi | J. Pergolizzi | P. Christo | D. Christo | F. Breve | Mark Coleman | Frank Breve
[1] Ding Lin,et al. Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges , 2022, Aging and disease.
[2] Xin Wang,et al. The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis , 2022, Cells.
[3] M. Tambuwala,et al. Overview of therapeutic targets in management of dementia. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[4] C. Hetz,et al. Cell death regulation by MAMs: from molecular mechanisms to therapeutic implications in cardiovascular diseases , 2022, Cell Death & Disease.
[5] Taher Entezari-Maleki,et al. Fluvoxamine and long COVID-19; a new role for sigma-1 receptor (S1R) agonists , 2022, Molecular Psychiatry.
[6] E. Giovannetti,et al. New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4 , 2022, Molecules.
[7] F. Vizeacoumar,et al. Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells , 2021, Pathogens.
[8] E. Lacivita,et al. σ2 Receptor and Its Role in Cancer with Focus on a MultiTarget Directed Ligand (MTDL) Approach , 2021, Molecules.
[9] A. Marais. Apolipoprotein E and Atherosclerosis , 2021, Current Atherosclerosis Reports.
[10] M. Prasanth,et al. The emerging role of the sigma-1 receptor in autophagy: hand-in-hand targets for the treatment of Alzheimer’s , 2021, Expert opinion on therapeutic targets.
[11] G. Rishton,et al. Sigma‐2 receptor antagonists rescue neuronal dysfunction induced by Parkinson’s patient brain‐derived α‐synuclein , 2020, Journal of neuroscience research.
[12] K. Fukunaga,et al. Wildtype σ1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity. , 2020, The Journal of biological chemistry.
[13] S. Regen. The Origin of Lipid Rafts. , 2020, Biochemistry.
[14] Taolei Sun,et al. Sigma-2 Receptor—A Potential Target for Cancer/Alzheimer’s Disease Treatment via Its Regulation of Cholesterol Homeostasis , 2020, Molecules.
[15] K. Fukunaga,et al. Wildtype sigma-1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity. , 2020, The Journal of biological chemistry.
[16] C. Belzung,et al. Cholesterol homeostasis: researching a dialogue between the brain and peripheral tissues. , 2020, Pharmacological research.
[17] R. Mach,et al. The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer , 2020, Cancers.
[18] D. Rossi,et al. The sigma-1 receptor antagonists, promising players in fighting neuropathic pain. , 2020, Pharmaceutical patent analyst.
[19] Hongwei Yu,et al. Sigma-1 receptor activity in primary sensory neurons is a critical driver of neuropathic pain , 2020, Gene Therapy.
[20] Frederick A. Heberle,et al. Lipid Rafts: Controversies Resolved, Mysteries Remain. , 2020, Trends in cell biology.
[21] L. Scorrano,et al. The cell biology of mitochondrial membrane dynamics , 2020, Nature Reviews Molecular Cell Biology.
[22] I. Jou,et al. Lipids and Alzheimer’s Disease , 2020, International journal of molecular sciences.
[23] S. Kourrich,et al. The Sigma-1 Receptor: When Adaptive Regulation of Cell Electrical Activity Contributes to Stimulant Addiction and Cancer , 2019, Front. Neurosci..
[24] K. Dill,et al. Proteostasis collapse is a driver of cell aging and death , 2019, Proceedings of the National Academy of Sciences.
[25] Ming-Chin Lin,et al. Association between Use of Statin and Risk of Dementia: A Meta-Analysis of Observational Studies , 2019, Neuroepidemiology.
[26] H. Schmidt,et al. The Molecular Function of σ Receptors: Past, Present, and Future. , 2019, Trends in pharmacological sciences.
[27] Yuanbo Wu,et al. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. , 2019, Mitochondrion.
[28] P. Cottone,et al. Role of Sigma Receptors in Alcohol Addiction , 2019, Front. Pharmacol..
[29] L. Romero,et al. Trends in Sigma-1 Receptor Research: A 25-Year Bibliometric Analysis , 2019, Front. Pharmacol..
[30] C. Chiang,et al. Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor , 2019, BMC cancer.
[31] D. Zamanillo,et al. Blockade of the Sigma-1 Receptor Relieves Cognitive and Emotional Impairments Associated to Chronic Osteoarthritis Pain , 2019, Front. Pharmacol..
[32] R. González-Ramírez,et al. Molecular Interplay Between the Sigma-1 Receptor, Steroids, and Ion Channels , 2019, Front. Pharmacol..
[33] Sungkwon Chung,et al. Elevated cellular cholesterol in Familial Alzheimer’s presenilin 1 mutation is associated with lipid raft localization of β-amyloid precursor protein , 2019, PloS one.
[34] Darjus F. Tschaharganeh,et al. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression , 2019, Cell.
[35] Colin W. Taylor,et al. Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP3-Evoked Ca2+ Signals through Sigma-1 Receptors , 2019, Cell reports.
[36] I. Danovitch,et al. Pain and Depression: A Systematic Review , 2018, Harvard review of psychiatry.
[37] K. Bollinger,et al. Sigma 1 receptor: A novel therapeutic target in retinal disease , 2018, Progress in Retinal and Eye Research.
[38] F. Berardi,et al. Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations. , 2018, Future medicinal chemistry.
[39] J. Bruna,et al. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy , 2018, Neural regeneration research.
[40] A. Carvalho,et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis , 2018, Scientific Reports.
[41] G. Bu,et al. Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease , 2018, Biological Psychiatry.
[42] Guillaume Thibault,et al. From the unfolded protein response to metabolic diseases – lipids under the spotlight , 2018, Journal of Cell Science.
[43] M. Hiriart,et al. TRPV1 channels and the progesterone receptor Sig-1R interact to regulate pain , 2018, Proceedings of the National Academy of Sciences.
[44] D. Engblom,et al. The Sigma-2 Receptor Selective Agonist Siramesine (Lu 28-179) Decreases Cocaine-Reinforced Pavlovian Learning and Alters Glutamatergic and Dopaminergic Input to the Striatum , 2017, Front. Pharmacol..
[45] Xiaojing Ma,et al. Role of sigma 1 receptor in high fat diet-induced peripheral neuropathy , 2017, Biological chemistry.
[46] T. Su,et al. Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases , 2017, Journal of Biomedical Science.
[47] M. Merlos,et al. The Sigma-1 Receptor Antagonist, S1RA, Reduces Stroke Damage, Ameliorates Post-Stroke Neurological Deficits and Suppresses the Overexpression of MMP-9 , 2017, Molecular Neurobiology.
[48] C. Hetz,et al. ER stress and the unfolded protein response in neurodegeneration , 2017, Nature Reviews Neurology.
[49] D. Leroith,et al. Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia , 2017, Oncogene.
[50] P. Cottone,et al. Sigma Receptors and Alcohol Use Disorders. , 2016, Handbook of experimental pharmacology.
[51] J. Vela,et al. Blockade of sigma 1 receptors alleviates sensory signs of diabetic neuropathy in rats , 2016, European journal of pain.
[52] H. Schmidt,et al. Structural Perspectives on Sigma-1 Receptor Function. , 2017, Advances in experimental medicine and biology.
[53] K. Hashimoto,et al. Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders. , 2017, Advances in experimental medicine and biology.
[54] B. Lucke-Wold,et al. Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection. , 2017, Advances in experimental medicine and biology.
[55] Jing Zhao,et al. The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma. , 2017, Advances in experimental medicine and biology.
[56] D. Grimm,et al. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells , 2016, Human molecular genetics.
[57] H. Schmidt,et al. Crystal structure of the human σ1 receptor , 2016, Nature.
[58] Prashant Mishra,et al. Metabolic regulation of mitochondrial dynamics , 2016, The Journal of cell biology.
[59] A. Ruoho,et al. Biochemical Pharmacology of the Sigma-1 Receptor , 2016, Molecular Pharmacology.
[60] C. Rousseaux,et al. Sigma receptors [σRs]: biology in normal and diseased states , 2015, Journal of receptor and signal transduction research.
[61] D. Schwarz,et al. The endoplasmic reticulum: structure, function and response to cellular signaling , 2015, Cellular and Molecular Life Sciences.
[62] F. Mollinedo,et al. Lipid rafts as major platforms for signaling regulation in cancer. , 2015, Advances in biological regulation.
[63] K. Fukunaga,et al. The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. , 2015, Journal of pharmacological sciences.
[64] M. Portero-Otín,et al. Lipidomics of human brain aging and Alzheimer's disease pathology. , 2015, International review of neurobiology.
[65] Nidhi Kaushal,et al. Sigma receptors as potential therapeutic targets for neuroprotection. , 2014, European journal of pharmacology.
[66] E. Schon,et al. Mitochondrial Genetics and Disease , 2014, Journal of child neurology.
[67] Zong-Wen Wu,et al. Sigma‐2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy , 2014, Medicinal research reviews.
[68] Jennifer G. Robinson,et al. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes , 2014, Neurology.
[69] I. Astsaturov,et al. Molecular Pathways Molecular Pathways : Sterols and Receptor Signaling in Cancer , 2013 .
[70] J. Huber,et al. SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation , 2013, Experimental Neurology.
[71] S. Kourrich,et al. Dynamic Interaction between Sigma-1 Receptor and Kv1.2 Shapes Neuronal and Behavioral Responses to Cocaine , 2013, Cell.
[72] D. Zamanillo,et al. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. , 2012, The journal of pain : official journal of the American Pain Society.
[73] G. Pasternak. Preclinical pharmacology and opioid combinations. , 2012, Pain medicine.
[74] C. Hetz. The unfolded protein response: controlling cell fate decisions under ER stress and beyond , 2012, Nature Reviews Molecular Cell Biology.
[75] R. Hotchkiss,et al. Sigma-2 ligands induce tumour cell death by multiple signalling pathways , 2012, British Journal of Cancer.
[76] F. Al-Mohanna,et al. A mutation in sigma‐1 receptor causes juvenile amyotrophic lateral sclerosis , 2011, Annals of neurology.
[77] R. Hotchkiss,et al. Characterization and Evaluation of Two Novel Fluorescent Sigma-2 Receptor Ligands as Proliferation Probes , 2011, Molecular imaging.
[78] K. Nagata,et al. Protein folding and quality control in the ER. , 2011, Cold Spring Harbor perspectives in biology.
[79] M. Hayden,et al. Cholesterol metabolism in Huntington disease , 2011, Nature Reviews Neurology.
[80] P. Gressens,et al. The Yin and Yang of Microglia , 2011, Developmental Neuroscience.
[81] S. Buch,et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. , 2010, Trends in pharmacological sciences.
[82] V. Perry,et al. Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.
[83] K. Hashimoto. Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? , 2009, CNS & neurological disorders drug targets.
[84] Tangui Maurice,et al. The pharmacology of sigma-1 receptors. , 2009, Pharmacology & therapeutics.
[85] P. Daley,et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter , 2009, Journal of Neural Transmission.
[86] Teruo Hayashi,et al. Sigma-1 receptor chaperones and diseases. , 2009, Central nervous system agents in medicinal chemistry.
[87] S. Kulkarni,et al. σ-1 receptors in major depression and anxiety , 2009, Expert review of neurotherapeutics.
[88] J. Entrena,et al. Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands , 2008, Current neuropharmacology.
[89] M. Ohyama,et al. Low density of sigma1 receptors in early Alzheimer’s disease , 2008, Annals of nuclear medicine.
[90] E. Aydar,et al. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. , 2007, Cancer research.
[91] Teruo Hayashi,et al. Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.
[92] Søren Vang,et al. Protein misfolding and human disease. , 2006, Annual review of genomics and human genetics.
[93] H. Hauri,et al. The ER-Golgi intermediate compartment (ERGIC): in search of its identity and function , 2006, Journal of Cell Science.
[94] R. Matsumoto,et al. Involvement of sigma (σ) receptors in the acute actions of methamphetamine: Receptor binding and behavioral studies , 2005, Neuropharmacology.
[95] J. Cedarbaum. Survival , 2004 .
[96] Teruo Hayashi,et al. σ‐1 Receptors potentiate epidermal growth factor signaling towards neuritogenesis in PC12 cells: Potential relation to lipid raft reconstitution , 2004, Synapse.
[97] Teruo Hayashi,et al. σ-1 Receptors (σ1 Binding Sites) Form Raft-Like Microdomains and Target Lipid Droplets on the Endoplasmic Reticulum: Roles in Endoplasmic Reticulum Lipid Compartmentalization and Export , 2003, Journal of Pharmacology and Experimental Therapeutics.
[98] L. Thal,et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.
[99] W. Bowen,et al. ς1 Receptor-Related Neuroactive Steroids Modulate Cocaine-Induced Reward , 2003, The Journal of Neuroscience.
[100] D. Newmeyer,et al. Mitochondria Releasing Power for Life and Unleashing the Machineries of Death , 2003, Cell.
[101] K. Zou,et al. Amyloid β‐protein affects cholesterol metabolism in cultured neurons: Implications for pivotal role of cholesterol in the amyloid cascade , 2002, Journal of neuroscience research.
[102] P. Romieu,et al. Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity , 2002, Neuroscience & Biobehavioral Reviews.
[103] W. Bowen,et al. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides , 2002, Neuropharmacology.
[104] G. Pasternak,et al. Sigma1 receptor modulation of opioid analgesia in the mouse. , 2002, The Journal of pharmacology and experimental therapeutics.
[105] P. Romieu,et al. Sigma(1) (sigma(1)) receptor antagonists represent a new strategy against cocaine addiction and toxicity. , 2002, Neuroscience and biobehavioral reviews.
[106] A. Johnson,et al. The translocon: a dynamic gateway at the ER membrane. , 1999, Annual review of cell and developmental biology.
[107] G. Pasternak,et al. Enhanced κ-opioid receptor-mediated analgesia by antisense targeting the σ1 receptor , 1997 .
[108] H. Glossmann,et al. High affinity of sigma1‐binding sites for sterol isomerization inhibitors: evidence for a pharmacological relationship with the yeast sterol C8–C7 isomerase , 1997, British journal of pharmacology.
[109] E. Kempner,et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[110] K. Jansen,et al. Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss , 1993, Brain Research.
[111] M. Brownstein. A brief history of opiates, opioid peptides, and opioid receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[112] R. Mulkey,et al. Action potentials must admit calcium to evoke transmitter release , 1991, Nature.
[113] W. Bowen,et al. Sigma receptors: biology and function. , 1990, Pharmacological reviews.
[114] C. Montigny,et al. N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors , 1990 .
[115] E. London,et al. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. , 1988, Science.
[116] S. Snyder,et al. Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.
[117] P. Sastry,et al. Lipids of nervous tissue: composition and metabolism. , 1985, Progress in lipid research.